Asthma exacerbation associated with COVID-19 pneumonia

Ono, Yoshitaka; Obayashi, Shohei; Horio, Yukihiro; Niimi, Kyoko; Hayama, Naoki; Ito, Yoko; Oguma, Tsuyoshi; Asano, Koichiro

doi:10.1016/j.alit.2020.07.002

Cited by 9 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We are reporting a rare case of suffering from COVID-19-related pneumonia with preexisting pediatric allergic asthma. As described above in our case with asthma, SARS-CoV-2 positivity in PCR testing and findings of typical ground glass-like opacity in chest CT were consistent with COVID-19 [ 5 – 7 ].…”

Section: Discussionsupporting

confidence: 79%

COVID-19-Related Pneumonia in an Adolescent Patient with Allergic Asthma

Özdemir

Engin

Yılmaz

2021

Case Reports in Medicine

View full text Add to dashboard Cite

Background. The latest coronavirus infection due to SARS-CoV-2, which started in China in December 2019, was announced as a pandemic by the World Health Organization (WHO) in March 2020. All epidemiological data so far show us that SARS-CoV-2 infection is less serious in children than in adults. Allergic asthma, the most common chronic disease in children, is usually not to be related to greater risk or severity for COVID-19 in pediatric populations. Although reports/research on asthma and COVID-19 in children have thus far been comforting, when coming across an asthma patient with any lower airway infection, attention should be given to evaluate their asthma control level and the possibility of SARS-CoV-2 infection. Case Report. Here, we report a rare adolescent case of COVID-19-related pneumonia development with underlying asthma. A 16-year-old male patient has been followed up by the pediatric allergy outpatient clinic with the diagnosis of asthma for the last 5 years. He was thought to have typical clinical and laboratory findings for SARS-CoV-2 infection combined with underlying pediatric (allergic) asthma. Pulmonary CT showed findings consistent with COVID-19-related pneumonia. He was discharged after 1 week when all his complaints regressed, his examination became normal, and 5-day favipiravir treatment was completed. Conclusion. When a physician comes across an asthma patient with any lower airway infection, attention should be given to evaluate their asthma control level and possibility of SARS-CoV-2 infection.

show abstract

Section: Discussionsupporting

confidence: 79%

COVID-19-Related Pneumonia in an Adolescent Patient with Allergic Asthma

Özdemir

Engin

Yılmaz

2021

Case Reports in Medicine

View full text Add to dashboard Cite

show abstract

“…Asthma exacerbations have rarely been documented in patients with COVID-19. Ono et al [ 8 ] reported on a case of exacerbation of previously well-controlled eosinophilic asthma associated with COVID-19 pneumonia. Codispoti et al [ 9 ] described four patients with asthma exacerbation also associated with COVID-19 infection.…”

Section: Discussionmentioning

confidence: 99%

Symptoms in patients with asthma infected by SARS-CoV-2

García-Pachón

Ruiz-Alcaraz

Baeza-Martínez

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

Introduction Organ tropism of SARS-CoV-2 to the respiratory tract could potentially aggravate asthma. The susceptibility of patients with asthma to develop an exacerbation when they are infected with SARS-CoV-2 is unknown. We aimed to investigate the symptoms presented in patients with asthma who became infected with SARS-CoV-2. Methods and Results All patients over 14 years of age who tested positive for SARS-CoV-2 (by RT-PCR) were included (n=2,995). In patients with asthma (n=77, 2.6%; 44 females), symptoms, therapy and phenotype were recorded. Seventeen (22%) patients had mild asthma, 55 (71%) moderate and five severe (6%). Twenty-six patients with asthma (34%) were asymptomatic, 34 (44%) developed symptoms but did not require hospital admission, and 17 (22%) were hospitalised. One patient was admitted because of asthma exacerbation without pneumonia or other symptoms. Ten patients (13%) had wheezes (six with pneumonia). Comparison of wheezing between patients with non-T2 asthma and the rest of the patients was statistically significant, ( p <0.001). Conclusions SARS-CoV-2 infection is not a significant cause of asthma exacerbation, although some patients may present wheezing, especially in cases of pneumonia. The severity of asthma does not seem to be associated with symptoms of the disease.

show abstract

“…Severity of COVID-19 was not affected in patients diagnosed with atopic dermatitis (AD) [ 25 ], an inflammatory disease, in which pathogenesis is characterized by type I hypersensitivity reaction [ 26 ]. However, it appears that SARS-CoV-2 infection could exacerbate asthma symptoms, as it was shown by Ono et al [ 27 ]. Also, similar to asthma, AD symptoms worsened during COVID-19 [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 88%

Exacerbation of Chronic Spontaneous Urticaria Symptoms in COVID-19 Patients, Case Report

Klyucharova

Мартынова

Rizvanov³

et al. 2022

BioNanoSci.

View full text Add to dashboard Cite

Chronic spontaneous urticaria (CSU) is characterized by wheals lasting more than 6 weeks and can be accompanied by angioedema. Treatment of the disease varies depending on the severity and includes first-line therapeutics such as non-sedative antihistamines. Second- and third-line treatments are used in severe and uncontrolled form of CSU. Environmental exposure and infections could trigger worsening symptoms. The goal of this study is to assess the effect of SARS-CoV-2 infection on CSU symptoms and the efficacy of the second- and third-line therapeutics for CSU management in COVID-19 patients. Our findings show that SARS-CoV-2 infection exacerbates CSU symptoms. Worsening of disease was indicated by decreased Urticaria Control Test (UCT) and increased Urticaria Activity Score (UAS). Treatment management was modified by switching to second- and third-line therapeutics; however, therapeutic control was achieved only in one patient. Our data demonstrates that SARS-CoV-2 infection contributes to the severity of CSU. Symptoms of CSU are more challenging to manage and require changes in treatment protocol, including second- and third-line therapeutics. We believe that severe inflammation triggered by SARS-CoV-2 infection contributes to the worsening of CSU symptoms.

show abstract

Asthma exacerbation associated with COVID-19 pneumonia

Cited by 9 publications

References 10 publications

COVID-19-Related Pneumonia in an Adolescent Patient with Allergic Asthma

COVID-19-Related Pneumonia in an Adolescent Patient with Allergic Asthma

Symptoms in patients with asthma infected by SARS-CoV-2

Exacerbation of Chronic Spontaneous Urticaria Symptoms in COVID-19 Patients, Case Report

Contact Info

Product

Resources

About